Clovis Oncology Announces 2M Share Offering by Selling Stockholders


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Clovis Oncology (Nasdaq: CLVS) announced today that certain selling stockholders have commenced an underwritten public offering of 2,000,000 shares of the Company's common stock which they recently acquired as consideration in connection with the Company's acquisition of EOS (Ethical Oncology Science) S.p.A. All net proceeds from the sale of the common stock will be received by the selling stockholders. The Company will not receive any of the proceeds, and the total number of shares of its outstanding common stock will not change as a result of the offering. J. P. Morgan Securities LLC is acting as the sole manager for the offering. In addition, the selling stockholders intend to grant J. P.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

See full press release

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Posted In: NewsGuidanceOfferingsGlobal